Objective:
To explore the potential of aptamer-functionalized contact lenses for enhanced ocular drug delivery and diagnostics, emphasizing their innovative approach.
Approach:
- Aptamers can bind to specific ocular targets with high affinity, enhancing drug delivery efficiency.
- FDA has approved two anti-VEGF aptamers for ocular diseases, indicating their therapeutic potential.
- Aptamer-functionalized hydrogels show promise for controlled drug delivery in chronic ocular conditions.
- Real-time monitoring of drug concentrations in tear fluid is feasible with aptamer-based biosensors, representing a significant advancement.
- Challenges with aptamer stability in tear fluid.
- Concerns regarding lens comfort and biocompatibility.
- Need for scalable and regulatory-compliant manufacturing processes.
- Ongoing research is needed to address these challenges effectively.
- Pelusi et al, 2023
- Santarpia and Carnes, 2024
- Bege et al, 2025
- Liu et al, 2023
- Abune et al, 2021
- Wong et al, 2023
- Korhonen et al, 2024
- Wong et al, 2024
- Shetty et al, 2024
- Wang et al, 2022
- Cao et al, 2023
Key Findings:
Interpretation:
Aptamer-functionalized contact lenses represent a novel approach to improve drug delivery and monitoring in ocular therapies, potentially transforming patient care and outcomes.
Limitations:
Conclusion:
Aptamer-functionalized contact lenses could revolutionize ocular drug delivery and diagnostics, though further research is needed to address existing challenges and foster interdisciplinary collaboration.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.